Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalent (CTLT)
NYSE:CTLT
Holding CTLT?
Track your performance easily
CTLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$42.11 - $63.50
Previous Close$63.48
Volume13.88M
Average Volume (3M)2.23M
Market Cap
$11.52B
Enterprise Value$16.12B
Total Cash (Recent Filing)$335.00M
Total Debt (Recent Filing)$4.93B
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Feb 11, 2025EPS Estimate
$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding181,511,586
10 Day Avg. Volume4,461,487
30 Day Avg. Volume2,227,022
Standard Deviation0.13
R-Squared0.22
Alpha-0.00316
Financial Highlights & Ratios
Price to Book (P/B)3.25
Price to Sales (P/S)2.61
Price to Cash Flow (P/CF)47.20
P/FCF Ratio41.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.65
Enterprise Value/Gross Profit16.92
Enterprise Value/Ebitda40.61
Forecast
1Y Price Target
$63.33Price Target Upside-0.24% Downside
Rating ConsensusHold
Number of Analyst Covering3
Catalent News
PremiumCompany Announcements
Catalent Acquired by Novo Holdings in $16.5 Billion Deal
PremiumCompany Announcements
Catalent Inc. Reports Q1 Fiscal 2025 ResultsBulls Say, Bears Say
Bulls Say
Biologics GrowthCatalysts that could potentially drive faster and more profitable Biologics growth include GLP-1s, growth in ELEVIDYS, and a recovery in biotech funding and demand.
Client OutlookFavorable outlook and updates for top client, Sarepta, suggest a promising partnership and future growth.
Financial PerformanceStrong FY4Q24 results and business development indicate positive momentum for the company.
Bears Say
Financial PerformanceCTLT's F1Q25 fell well short on Biologics revenue and margin while PCH remains on track.
Market PositionNotable decline in NTM backlog and backlog visibility.
Operational ChallengesBiologics requires more time before achieving normal growth and profitability as EBITDA margin retraced to ~10%.
---
Ownership Overview
0.01% Insiders
25.80% Mutual Funds
30.44% Other Institutional Investors
27.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTLT FAQ
What was Catalent’s price range in the past 12 months?
Catalent lowest stock price was $42.11 and its highest was $63.50 in the past 12 months.
What is Catalent’s market cap?
Currently, no data Available
When is Catalent’s upcoming earnings report date?
Catalent’s upcoming earnings report date is Feb 11, 2025 which is in 52 days.
How were Catalent’s earnings last quarter?
Catalent released its earnings results on Nov 05, 2024. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of $0.045 by -$0.175.
Is Catalent overvalued?
According to Wall Street analysts Catalent’s price is currently Overvalued.
Does Catalent pay dividends?
Catalent does not currently pay dividends.
What is Catalent’s EPS estimate?
Catalent’s EPS estimate is $0.03.
How many shares outstanding does Catalent have?
Catalent has 146,309,000 shares outstanding.
What happened to Catalent’s price movement after its last earnings report?
Catalent reported an EPS of -$0.13 in its last earnings report, missing expectations of $0.045. Following the earnings report the stock price went down -0.358%.
Which hedge fund is a major shareholder of Catalent?
Among the largest hedge funds holding Catalent’s share is Elliott Investment Management LP. It holds Catalent’s shares valued at 242M.
---
Catalent Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$63.33 (-0.24% Downside)
$63.33 (-0.24% Downside)
Blogger Sentiment
Neutral
CTLT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 288.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $167.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-11.19%
Trailing 12-Months
Asset Growth
-3.14%
Trailing 12-Months
Company Description
Catalent
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.
---
CTLT Company Deck
---
CTLT Earnings Call
Q1 2023
0:00 / 0:00
---
CTLT Stock 12 Month Forecast
Average Price Target
$63.33
▼(-0.24% Downside)
Technical Analysis
Best Analysts Covering CTLT
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
+10.85%
downgraded a sell rating 7 months ago
Copying David Toung's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +10.85% per trade.
---